title: [Efficacy of monotherapy with 15 antihypertensive agents in treating essential hypertension assessed by 24-hour ambulatory blood pressure monitoring].
abstract: OBJECTIVE
  To evaluate the efficacy of the monotherapy of 15 agents in treating essential hypertension.
  
  
  METHODS
  After 2-week wash-out, a total of 370 patients with seated diastolic blood pressure 95-114 mmHg and seated systolic blood pressure < 180 mmHg were randomized to different therapeutic groups. 24-hour ambulatory blood pressure monitoring was performed before medication and at the end of 8 weeks.
  
  
  RESULTS
  All the agents significantly reduced the 24 hour mean blood pressures after treatment except doxazosin, terazosin, and torasemide.
  
  
  CONCLUSIONS
  The result suggested that the angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers and long-acting calcium antagonists were effective in treating essential hypertension, while the low-dose doxazosin, terazosin and torasemide can be used for combination therapy but not for monotherapy.
authors.affiliation: Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Fuwai Cardiovascular Diseases Hospital, CAMS and PUMC, Beijing 100037, China.
authors.forename: Cong-Xiao
authors.initials: CX
authors.lastname: Hua
authors.forename: Lu
authors.initials: L
authors.lastname: Hua
authors.forename: Na
authors.initials: N
authors.lastname: Li
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Hui-Min
authors.initials: HM
authors.lastname: Pang
authors.forename: Guang-Hua
authors.initials: GH
authors.lastname: Ming
authors.forename: Yan
authors.initials: Y
authors.lastname: Huang
authors.forename: Xiao-Ru
authors.initials: XR
authors.lastname: Cheng
authors.forename: Hong
authors.initials: H
authors.lastname: Liu
authors.forename: Ying
authors.initials: Y
authors.lastname: Wu
authors.forename: Li
authors.initials: L
authors.lastname: Xu
authors.forename: Jian
authors.initials: J
authors.lastname: Kang
authors.forename: Zhi-Min
authors.initials: ZM
authors.lastname: Xu
authors.forename: Yi-Shi
authors.initials: YS
authors.lastname: Li
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000145:classification / Q000627:therapeutic use*; D018660:Blood Pressure Monitoring, Ambulatory; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D017292:Doxazosin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D000077786:Torsemide; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D013449:Sulfonamides; C041226:Terazosin; D017292:Doxazosin; D000077786:Torsemide; D011224:Prazosin